Celgene
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Celgene sits in the top decile of US sponsors by registered trial count (#115 of 15,742 sponsors by registered trial count).
Celgene: 308 sponsored US clinical trials, 12 recruiting.
Celgene sponsors 308 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 221 completed. 57 of these trials are in Phase 3-4 (later-stage) and 236 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 11 trials.
Top-decile sponsor footprint
Celgene ranks in the top decile of sponsors by registered trial count (#115 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
221 of 282 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
308 total, page 4 of 7
Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension
NCT02521714
Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis
NCT02510937
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02406742
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
NCT02502188
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
NCT02281084
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
NCT02435992
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
NCT02267707
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
NCT02400242
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
NCT02921828
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
NCT02343536
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
NCT02289456
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
NCT02301143
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
NCT02330562
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
NCT02367183
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
NCT02341781
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
NCT02374099
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
NCT02367196
PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects
NCT02387866
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
NCT02285062
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
NCT02269943
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
NCT02323906
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
NCT02309177
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
NCT02250326
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
NCT02313012
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)
NCT02279654
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
NCT02273739
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
NCT02294058
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
NCT02124850
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
NCT02223052
Radiolabeled Study of CC-122 in Healthy Subjects
NCT02234999
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
NCT02185040
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
NCT02189343
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
NCT02098473
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
NCT02151149
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
NCT02103335
Food Effect and CYP1A2 Induction Study in Healthy Subjects
NCT02168205
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
NCT01946477
Relative Bioavailability Study of CC-292
NCT02433457
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT01996865
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
NCT01964430
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
NCT01997840
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
NCT02027428
Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study
NCT02049528
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
NCT02021500
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
NCT02031419
Connect® Myeloid Disease Registry
NCT01688011
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
NCT01962103
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
NCT02047734
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
NCT01938001
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
NCT01835587
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 161 |
| Phase 2 | 75 |
| Phase 3 | 56 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Celgene pipeline
12 recruiting of 308 indexed (4% open); 221 completed (72%).
Phase mix: 57 late (III/IV) vs 236 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Celgene: open-pipeline peers nationwide
Peers matched on 308 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Celgene sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 308 trials (± recruiting share)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 305 trials · 8% recruiting
- Allergan · 314 trials · 0% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
Sponsors near 4% open enrollment (± trial volume)
- U.S. Army Medical Research and Development Command · 4% recruiting · 77 trials
- MedtronicNeuro · 4% recruiting · 51 trials
- Aldeyra Therapeutics · 4% recruiting · 26 trials
- DexCom · 4% recruiting · 26 trials
Related
What to do with this Celgene page
308 registered trials is a research-attention snapshot, not an endorsement of Celgene or any single study.
- 12 of Celgene's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Celgene studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Celgene pipeline card: 308 registered trials from official public datasets.Report a data error.